Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total HIV Franchise Product Sales — Europe sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, FY2025
2,392
Period ended Dec 31, 2025
Change on a year earlier
+2.3%
2,339 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HIV Franchise Product Sales — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,392 | +2.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 2,339 | +11.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 2,102 | -5.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 2,219 | -6.2% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 2,366 | +3.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 2,287 | -1.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 2,312 | -1.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 2,350 | -8.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 2,575 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2019-02-04) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HIV Franchise Product Sales — Europe sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv_total_eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.